A new joint report from the Association of the British Pharmaceutical Industry (ABPI) and the National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs) concludes that the United Kingdom stands on the brink of a transformative shift in how new medicines are discovered and developed, driven by human-relevant pre-clinical models that could markedly accelerate drug pipelines, reduce late-stage failures and bolster the country’s competitiveness in global life sciences.
The review, published this week, argues that systems rooted in human biology, including organ-on-a-chip, advanced cellular assays and computational modelling, are no longer futuristic concepts but mature platforms ready for broader adoption. It calls for a “translational hub” to be established under the government’s 2025 Life Sciences Plan, a centralised infrastructure to standardise, validate and scale next-generation models across academia, industry and the NHS.
For decades, the early stages of drug discovery have relied heavily on animal models. While these systems have contributed significantly to medical advances, they frequently fall short in predicting human responses, leading to costly failures in clinical trials. According to some industry estimates, only one in 10 experimental medicines that enter clinical evaluation ultimately achieves regulatory approval, with lack of efficacy or unforeseen safety issues among the chief reasons for attrition.
The ABPI-NC3Rs review highlights that human-relevant models,such as microphysiological systems, primary human cell systems, artificial intelligence-driven simulations and multi-omics platforms, offer a path to more predictive science. These technologies can mimic human tissue architecture and function, modelling disease processes and drug interactions more faithfully than traditional animal models.
Dr Samantha Leigh, interim CEO of NC3Rs, said: “We are at an inflection point. Scientific advances, coupled with regulatory openness to alternative models, mean that we can now pursue approaches that better represent human biology. This isn’t about replacing science, it’s about enhancing it.”
Economic and Scientific Opportunity
The report places the UK’s strong foundation in advanced biosciences at the heart of its case. Britain’s world-class universities, biotech clusters, especially in Cambridge, Oxford and London, and a vibrant SME ecosystem give it competitive advantages in modelling technologies, high-content imaging, systems biology and AI integration.
Estimates suggest that adopting human-relevant pre-clinical models more widely could reduce late-stage clinical trial failures by up to 30 % and shorten the development timeline by months or even years, translating directly into economic gains for industry and health systems. For the UK, where life sciences contributed an estimated £83 billion to the economy in 2024, innovation in the discovery pipeline could reinforce growth and draw international investment.
The authors underscore that the proposed translational hub could serve as a focal point for cross-sector collaboration, standardisation of protocols, training for scientists and regulatory engagement, including with bodies such as the Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA).
The timing of the report aligns with mounting global interest in refining pre-clinical science. Regulatory agencies in the US and EU have signalled increasing receptivity to data from advanced human-relevant systems, particularly when they are used to complement or challenge traditional animal data.
Professor Mark Henderson, ABPI’s director of research and innovation, said: “Regulators are no longer apprehensive about alternative models. They want robust, validated science, and that’s exactly what the UK can help deliver. Our ambition should be to set international standards, not follow them.”
Countries such as the Netherlands and Germany already host national programmes integrating organ-on-a-chip and computational pharmacology into public-private research streams. The ABPI-NC3Rs review positions the UK as well placed to compete at this frontier, especially with the structural support proposed under the 2025 Life Sciences Plan.
Despite technological momentum, the report acknowledges persistent barriers. Fragmented funding, inconsistent validation standards and siloed expertise can impede cross-institutional uptake. Smaller biotech firms, in particular, may find it difficult to access high-cost platforms or the specialised talent required to operate them.
A centralised translational hub could address these gaps by:
- Providing shared infrastructure for cutting-edge model systems
- Developing standardised validation and quality frameworks
- Offering training programmes for academia and industry staff
- Coordinating regulatory engagement and data sharing
Such a hub would not replace existing centres of excellence, it would connect them.
Implications for Drug Development and Patients
For patients and clinicians, the benefits of improved pre-clinical models could be profound. More predictive early testing means that therapeutic candidates entering human trials are more likely to succeed, reducing patient exposure to ineffective or unsafe compounds and accelerating access to genuinely transformative medicines. Conditions with historically high failure rates, such as Alzheimer’s, certain cancers and rare genetic diseases, stand to benefit most from advances in disease modelling.
The UK’s NHS Innovation Accelerator and Medicines Discovery Catapult are among the entities already bridging discovery and clinical translation. The proposed translational hub would link these efforts to foundational science, creating a continuum from molecular hypothesis to patient outcome.
As the government refines delivery plans for the Life Sciences Plan, stakeholders across industry and academia will be watching closely. The ABPI-NC3Rs review makes a compelling case that the UK’s future competitiveness in life sciences hinges not just on clever molecules or big data, but on whether it can harness human biology more effectively in the earliest phases of medicine discovery.
Whether policymakers commit to a dedicated translational hub, and how quickly, will be a key test of the UK’s strategic ambition. In an era where predictive science matters as much as molecular innovation, the nation’s ability to lead on human-relevant pre-clinical models may become a defining edge in global health research.